Eram Khan

Eram Khan is a partner in Goodwin’s Antitrust and Competition practice, based in London. With over a decade of experience, she advises clients on the full spectrum of competition law matters, offering strategic counsel across a wide range of industries.

Eram has particular expertise in the life sciences, private equity, financial services, and mining sectors. She is a trusted adviser to major corporates, investment banks, institutional investors, and private equity firms, guiding them through complex international transactions. Her practice focuses on EU, UK, and multi-jurisdictional merger control, foreign investment screening, and conduct issues.

She also has significant experience representing leniency applicants in European Commission cartel investigations, and regularly advises on compliance programs and market studies conducted by competition and financial regulatory authorities in both the EU and the UK.

Eram’s international perspective is shaped by her time working in Brussels and her in-house secondment with the Competition team of a leading UK retail bank, giving her a practical understanding of regulatory expectations and commercial drivers.

Eram’s representative experience includes advising:

• MeridianLink on its $2 billion acquisition by Centerbridge Partners, a global investment firm
• LumiThera, an ophthalmic medical device company, on its acquisition by Alcon
• Vicebio, a biotech firm developing next-generation vaccines for respiratory viruses, on its $1.6 billion acquisition by Sanofi
• Color Wow, one of the fastest-growing US/UK-based haircare brands, on its acquisition by L’Oréal
• Ferrara’s European holding company, part of the Ferrero group, on its acquisition of CPK Group, a leading French confectionery and chocolate company
• Teleflex Inc, a global provider of medical technologies, on its acquisition of the vascular intervention business of Biotronik SE & Co. KG
• SevenRooms, a CRM, marketing, and operations platform for the hospitality industry, on its acquisition agreement with DoorDash
• Anthos Therapeutics on its acquisition by Novartis for up to $3.1 billion
• Eidos Therapeutics and BridgeBio International GmbH on their exclusive license agreement to develop and commercialize acoramidis as a treatment for transthyretin amyloidosis in Europe with Bayer Consumer Care AG
• Isovalent Inc., a cloud native networking and security solutions provider, on its acquisition by Cisco Systems, Inc
• The Telegraph Media Group and the independent directors on its Board in connection with the public interest review of its proposed acquisition by Redbird IMI
• TA Associates and Warburg Pincus on their investment in Epassi Group, a leading digital payments provider for employee benefits, from Bregal Milestone, and subsequent combination with the Exercite Group, a B2B fitness platform previously owned by Waterland
• Envato, a leading online platform for creative assets and tools, on its agreement to sell its entire issued share capital to Shutterstock
• Arlington Capital and its portfolio company BlueHalo on its $4.1 billion all-stock acquisition by AeroVironment
• TA Associates on its acquisition of a majority stake in Solifi, a global fintech software provider for secured finance, from existing investor Thoma Bravo
• Versanis Bio on its acquisition by Eli Lilly for up to $1.925 billion
• Inversago Pharma on its $1.7 billion acquisition by Novo Nordisk
• Globus Medical, a leading musculoskeletal solutions company, on its definitive agreement to combine in an all-stock transaction with NuVasive
• TCR2 Therapeutics on its strategic combination with Adaptimmune Therapeutics to create a preeminent cell therapy company focused on treating solid tumors
• Qualtrics International on its $12.5 billion sale to Silver Lake and CCP Investments
• SunMed Group on its definitive agreement to acquire the respiratory health business of Avanos Medical, Inc.
• A consortium of banks led by JP Morgan and Standard Chartered on the antitrust considerations relating to the restructuring of their positions on the London Metal Exchange (LME), held on behalf of stainless steel producer Tsingshan Holdings Group following a short squeeze in the nickel market*
• SSE Thermal and Equinor on their acquisition of Triton Power Holdings Ltd from Energy Capital Partners*
• Glencore on the multi-jurisdictional merger control clearances for its acquisition of its remaining stake in the Cerrejón coal mine in Colombia from its joint venture partners, Anglo American and BHP*
• Alinda Capital Partners on the sale of its majority stake in Energy Assets Group, a UK-based metering and energy service business, to an international consortium buyer*
• Jingye Group, a Chinese steel company, on the merger control aspects of its acquisition of certain assets of British Steel*
• Advent International on the merger control clearances for its ₤1 billion recommended cash offer for Laird*
• Cerberus Capital Management on its acquisition of Worldwide Flight Services, one of the world’s leading providers of air cargo and ground handling services*
• Lloyds Banking Group on the acquisition of Tesco Bank’s prime ₤3.7 billion UK residential mortgage portfolio and the acquisition of Zurich’s UK workplace pensions and savings business*
• Deutsche Börse on the European Commission’s in-depth investigation into its proposed ₤21 billion merger with the London Stock Exchange Group*
• Novartis on the EU and global merger clearances for its transformational three-way, inter-conditional asset swap with GSK concerning oncology, vaccines and consumer health products (GCR Matter of the Year and FT Innovative Lawyers Award)*
• Glencore on various merger control and competition law compliance matters, including its $70 billion acquisition of the remaining stake in Xstrata and on their $775.2 million sale of a 51% stake in its global oil storage business to HNA*
• An automotive parts company as the immunity applicant in the European Commission’s investigation concerning various automotive components, forming part of what has been described as the “largest cartel investigation in history”*

*Denotes experience prior to joining Goodwin

Eram is a member of the Competition Section Committee of the Law Society of England and Wales. She also holds memberships in the Antitrust Sections of the American Bar Association and the International Bar Association.

Prior to joining Goodwin, Eram was counsel at Linklaters LLP in London.

Eram has been recognized as a ‘Future Leader’ by Who’s Who Legal Competition in (2020-2025) guides.

• Co-Author, “Goodwin Antitrust & Regulatory Shorts: Resale Price Fixing in Fashion - EU Imposes an $182M Fine on Gucci, Chloé & Loewe,” Goodwin Client Alert, October 2025
• Co-Author, “Antitrust Life Sciences Quarterly Update 2025 Q2,” Goodwin Insight, August 2025
• Co-Author, “Antitrust and Competition Life Sciences Year in Review 2024,” Goodwin Insight, February 2025
• Co-Author, “In a Landmark Judgment, Top European Court Curbs European Commission’s Ability to Review ‘Killer Acquisitions,’” Goodwin Client Alert, September 2024
• Co-Author, “European Commission’s First-Ever Abuse of Dominance Probe for Shelving of a Novel Pipeline Therapy,” Goodwin Insight, April 2024
• Co-Author, “CJEU Confirms Competition Authorities’ Power to Investigate GDPR Violations and Provides Insights into Personalised Social Media Advertising and GDPR Compliance,” Goodwin Data, Privacy + Cybersecurity Insights, September 2023 
• Co-Author, “The Digital Markets, Competition, and Consumers Bill,” Goodwin Client Alert, June 2023